Merck & Co., Inc. (NYSE:MRK) Receives $83.08 Average PT from Brokerages

Share on StockTwits

Shares of Merck & Co., Inc. (NYSE:MRK) have received a consensus recommendation of “Buy” from the eighteen ratings firms that are currently covering the stock, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $83.79.

MRK has been the topic of a number of recent research reports. Bank of America upped their price target on Merck & Co., Inc. from $90.00 to $91.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. Argus upped their price target on Merck & Co., Inc. to $95.00 and gave the company a “buy” rating in a research report on Wednesday, February 20th. Cantor Fitzgerald initiated coverage on Merck & Co., Inc. in a research report on Friday, February 22nd. They set an “overweight” rating and a $95.00 price target on the stock. BMO Capital Markets upped their price target on Merck & Co., Inc. from $83.00 to $84.00 and gave the company a “market perform” rating in a research report on Wednesday, May 1st. Finally, ValuEngine raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd.

Shares of NYSE MRK traded up $0.30 during trading on Monday, reaching $83.08. 2,732,346 shares of the stock traded hands, compared to its average volume of 8,654,754. Merck & Co., Inc. has a 52-week low of $59.80 and a 52-week high of $84.27. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.37 and a quick ratio of 1.06. The firm has a 50-day moving average of $79.73. The stock has a market cap of $213.13 billion, a PE ratio of 19.14, a P/E/G ratio of 1.96 and a beta of 0.55.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, April 30th. The company reported $1.22 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.17. Merck & Co., Inc. had a return on equity of 39.85% and a net margin of 19.50%. The firm had revenue of $10.82 billion for the quarter, compared to analysts’ expectations of $10.45 billion. During the same quarter in the prior year, the firm earned $1.05 EPS. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. Equities analysts anticipate that Merck & Co., Inc. will post 4.72 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, July 8th. Investors of record on Monday, June 17th will be paid a dividend of $0.55 per share. The ex-dividend date of this dividend is Friday, June 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.65%. Merck & Co., Inc.’s payout ratio is 50.69%.

In related news, EVP Robert M. Davis sold 192,572 shares of the business’s stock in a transaction on Monday, March 25th. The stock was sold at an average price of $82.38, for a total transaction of $15,864,081.36. Following the sale, the executive vice president now directly owns 330,232 shares in the company, valued at approximately $27,204,512.16. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Merck & Co., Inc. acquired 4,121,683 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The shares were bought at an average price of $16.00 per share, for a total transaction of $65,946,928.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 445,308 shares of company stock worth $36,421,320. 0.27% of the stock is currently owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in MRK. UNIVEST FINANCIAL Corp increased its stake in Merck & Co., Inc. by 6.8% in the 4th quarter. UNIVEST FINANCIAL Corp now owns 15,030 shares of the company’s stock worth $1,148,000 after acquiring an additional 961 shares during the last quarter. Jolley Asset Management LLC increased its stake in Merck & Co., Inc. by 4.4% in the 4th quarter. Jolley Asset Management LLC now owns 60,665 shares of the company’s stock worth $4,635,000 after acquiring an additional 2,533 shares during the last quarter. Cavalier Investments LLC bought a new position in Merck & Co., Inc. in the 4th quarter worth about $1,195,000. First Personal Financial Services increased its stake in Merck & Co., Inc. by 118.2% in the 4th quarter. First Personal Financial Services now owns 9,182 shares of the company’s stock worth $702,000 after acquiring an additional 4,974 shares during the last quarter. Finally, Venturi Wealth Management LLC bought a new position in Merck & Co., Inc. in the 4th quarter worth about $299,000. Institutional investors own 75.08% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Recommended Story: What are Bollinger Bands?

Analyst Recommendations for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Rio Tinto  Stock Rating Lowered by Renaissance Capital
Rio Tinto Stock Rating Lowered by Renaissance Capital
Credit Suisse Group Upgrades Ctrip.Com International  to Outperform
Credit Suisse Group Upgrades Ctrip.Com International to Outperform
AtriCure  Raised to “Buy” at Zacks Investment Research
AtriCure Raised to “Buy” at Zacks Investment Research
Brooks Automation  Lowered to Hold at Zacks Investment Research
Brooks Automation Lowered to Hold at Zacks Investment Research
Workhorse Group  Lifted to “Buy” at BidaskClub
Workhorse Group Lifted to “Buy” at BidaskClub
Funko  Price Target Raised to $28.00
Funko Price Target Raised to $28.00


 
© 2006-2019 Zolmax.